Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
← catalyst calendarSponsored by Celyad Oncology SA (industry) · CYAD.BR — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
34estimated
Sites
5
Countries
Belgium, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-22 | actual | When the study began enrolling |
| Primary completion | 2023-08-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2038-05-25 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-03-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Unresectable Metastatic Colorectal Cancer
Interventions
- Drug: CYAD-101
- Drug: FOLFOX
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFThe Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'
measured Up to 73 days post first study treatment administration
The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15])
measured Up to 94 days post first study treatment administration
Permalink · CYAD.BR's whole pipeline · Catalyst calendar · Every registered study · What changed